Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Allergan/Ligand initiates 10 ALRT1057 oral retinoid Phase IIb trials.

  • News

Executive Summary

LIGAND/ALLERGAN INITIATE 10 ALRT1057 PHASE IIb TRIALS using the oral 9-cis-retinoic acid compound, Irvine, Calif.-based Allergan and San Diego-based Ligand announced May 23. The compound will be studied in non-Hodgkin's lymphomas, renal cell carcinoma (two studies of ALRT1057 plus alpha interferon), squamous cell carcinoma of the head and neck (ALRT1057 plus cisplatin), ovarian cancer (ALRT1057 plus cisplatin), patients with HIV (with the National Cancer Institute), AIDS-related Kaposi's sarcoma, hormone refractory prostate cancer, acute promyelocytic leukemia and multiple myeloma. Phase II trials are ongoing for a topical formulation for KS and mycosis fungoides.

Table

View full table

Tags:
Latest Headlines

Danes Advise Pharma Firms To Test Their Anti-Tamper Devices

Joint Clinical Assessments: EU Guidance On Evidence May Be Flexible For ATMPs And Single Arm Trials

Experts Urge Action On Regulatory Science Collaboration In Korea

Cancer Trials: FDA Wants Lower Performance Status Eligibility But Primary Analysis Exclusion OK

See All
UsernamePublicRestriction

Register

PS026258

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By